pregnanc
matern
immun
respons
chang
dramat
cours
gestat
implic
gener
lactogen
immun
subsequ
protect
suckl
neonat
enter
viral
infect
exampl
porcin
epidem
diarrhea
viru
pedv
alphacoronaviru
caus
acut
diarrhea
neonat
piglet
due
high
virul
pedv
immatur
immun
system
neonat
suckl
piglet
passiv
lactogen
immun
pedv
induc
pregnanc
via
gutmammari
gland
mg
secretori
iga
siga
axi
critic
piglet
protect
howev
antipedv
immun
respons
pregnanc
stage
gestat
requir
optim
stimul
gutmgsiga
axi
undefin
hypothes
gestat
window
nonleth
pedv
infect
pregnant
gilt
influenc
maximum
lymphocyt
mucos
traffick
mg
result
optim
passiv
lactogen
protect
suckl
piglet
understand
stage
gestat
affect
matern
immun
respons
pedv
three
group
gilt
oral
infect
pedv
first
second
third
trimest
control
mock
gilt
inocul
medium
third
trimest
determin
lactogen
immun
correl
protect
piglet
pedvchalleng
day
postpartum
pedv
infect
gilt
differ
stage
gestat
significantli
affect
multipl
matern
system
immun
paramet
prepartum
includ
cytokin
b
cell
pedv
antibodi
ab
pedv
antibodi
secret
cell
asc
pregnant
second
trimest
gilt
significantli
higher
level
circul
pedv
iga
igg
ab
asc
pedv
viru
neutral
vn
ab
post
pedv
infect
coincid
significantli
higher
pedv
ab
respons
second
trimest
gilt
surviv
rate
pedvchalleng
piglet
compar
first
third
mock
litter
respect
addit
piglet
surviv
posit
correl
pedv
langel
et
al
gestat
stage
impact
pedv
immun
iga
ab
asc
vn
ab
milk
pedv
iga
igg
ab
piglet
serum
find
implic
gestat
time
oral
attenu
pedv
matern
vaccin
wherebi
pedv
intestin
infect
second
trimest
optim
stimul
gutmgsiga
axi
result
lactogen
immun
protect
suckl
piglet
diarrheal
diseas
young
anim
account
estim
multimillion
dollar
loss
livestock
industri
annual
due
livestock
industri
annual
due
mortal
reduc
weight
gain
treatment
cost
trade
sanction
export
anim
product
infect
countri
exampl
porcin
epidem
diarrhea
viru
pedv
highli
virul
reemerg
enter
coronaviru
caus
acut
diarrhea
dehydr
death
neonat
piglet
kill
million
piglet
sinc
emerg
us
adult
pig
pedv
caus
wateri
diarrhea
depress
anorexia
well
agalactia
reduc
reproduct
perform
lactogen
immun
remain
promis
effect
way
protect
neonat
suckl
piglet
enter
diseas
like
pedv
depend
traffick
pathogenspecif
iga
plasmablast
mammari
gland
mg
accumul
secretori
iga
siga
antibodi
ab
milk
defin
gutmgsiga
axi
understand
regul
mucos
home
receptor
chemokin
express
critic
gener
suffici
lactogen
immun
piglet
protect
exampl
chemokin
receptor
ccr
lymphocyt
gut
home
marker
requir
iga
plasmablast
recruit
mg
mice
human
addit
increas
lymphocyt
migrat
mg
swine
end
gestat
lactat
coincid
increas
integrin
anoth
lymphocyt
gut
home
marker
b
cell
identifi
factor
influenc
lymphocyt
migrat
gutmgsiga
axi
may
lead
improv
pedv
vaccin
regimen
gestat
swine
boost
overal
herd
immun
health
industri
product
matern
vaccin
increas
amount
passiv
transfer
protect
ab
milk
induc
via
gutmgsiga
axi
strategi
use
protect
suckl
piglet
pedv
immedi
birth
exampl
swine
high
rate
protect
anoth
porcin
enter
alphacoronaviru
transmiss
gastroenter
viru
tgev
piglet
achiev
pregnant
sow
oral
infect
live
virul
viru
increas
rate
protect
associ
high
titer
iga
ab
colostrum
milk
demonstr
enter
viral
infect
stimul
intestin
mucosa
influenc
lactogen
immun
via
gutmgsiga
axi
model
system
use
context
pedv
similar
matern
vaccin
strategi
need
initi
gutmgsiga
axi
piglet
protect
show
previous
third
trimest
pregnant
gilt
administ
higher
dose
virul
pedv
increas
viru
neutral
vn
ab
titer
colostrummilk
piglet
protect
compar
lower
dose
despit
field
report
demonstr
incomplet
variabl
protect
oral
pedvinfect
gestat
swine
furthermor
optim
stage
gestat
initi
gutmgsiga
axi
mean
natur
infect
oral
vaccin
pregnant
swine
gener
protect
lactogen
immun
unknown
pregnanc
modul
immunolog
process
chang
cours
gestat
exampl
first
trimest
gestat
level
innat
proinflammatori
factor
increas
facilit
embryo
implant
pregnanc
progress
inflammatori
cytokin
decreas
regulatori
cell
cytokin
increas
support
fetal
growth
develop
prevent
reject
fetu
third
trimest
gestat
immunoregulatori
environ
retain
immedi
prior
parturit
proinflammatori
tissu
repair
factor
increas
promot
contract
uteru
expuls
fetu
placenta
abil
pregnanc
differenti
modul
immun
respons
explain
sever
ill
efficaci
vaccin
depend
stage
gestat
exampl
risk
sever
influenza
malaria
listeria
higher
women
third
trimest
gestat
stage
addit
women
vaccin
trival
inactiv
influenza
vaccin
seroconvers
rate
higher
late
third
trimest
compar
first
trimestervaccin
women
due
differ
immun
respons
differ
stage
pregnanc
import
consid
stage
gestat
design
vaccin
aim
increas
lactogen
immun
passiv
transfer
protect
ab
colostrummilk
mother
neonat
studi
infect
pregnant
first
pariti
gilt
first
second
third
trimest
gestat
pedv
determin
impact
stage
gestat
gener
matern
bcell
immun
gutmgsiga
axi
lactogen
immun
protect
pedv
challeng
piglet
goal
identifi
innat
adapt
immun
factor
pregnanc
influenc
lymphocyt
traffick
addit
immun
correl
lactogen
immun
protect
neonat
suckl
piglet
understand
impact
stage
gestat
pedv
infect
exposur
matern
immun
allow
precis
matern
vaccin
protocol
target
time
anim
immunolog
respons
optim
vaccin
efficaci
gestat
lactat
anim
enhanc
lactogen
immun
neonat
decreas
morbid
mortal
associ
neonat
enter
diseas
overal
summari
statist
signific
result
tabl
illustr
pedv
infect
gilt
differ
stage
gestat
figur
affect
multipl
matern
system
immun
paramet
prepartum
includ
natur
killer
nk
cell
cytokin
b
cell
pedv
ab
antibodi
secret
cell
asc
addit
signific
postpartum
effect
lactogen
immun
paramet
colostrum
milk
observ
includ
significantli
increas
pedv
iga
colostrum
milk
igg
colostrum
asc
pedv
iga
ab
vn
ab
pedvinfect
second
trimest
gilt
tabl
notabl
sever
gilt
pedv
iga
colostrum
milk
igg
colostrum
asc
ab
vn
ab
piglet
serum
pedv
iga
igg
ab
paramet
posit
correl
piglet
surviv
rate
tabl
demonstr
associ
iga
asc
ab
vn
ab
lactogen
immun
protect
suckl
neonat
detail
result
paramet
describ
follow
section
third
trimest
gilt
significantli
higher
pedv
rna
shed
titer
sever
pedvinduc
diarrhea
third
trimest
gilt
significantli
higher
pedv
rna
shed
titer
pid
compar
second
trimest
gilt
figur
addit
second
trimest
gilt
delay
onset
pedv
rna
shed
compar
first
third
trimest
gilt
fecal
consist
score
pid
significantli
higher
third
compar
second
first
trimest
gilt
third
trimest
gilt
treatment
group
clinic
diarrhea
mean
fecal
consist
score
figur
circul
nk
cell
frequenc
significantli
higher
first
trimest
gilt
pid
compar
second
third
trimest
gilt
figur
pid
peripher
nk
cell
activ
significantli
higher
first
compar
second
third
trimest
gilt
figur
mean
concentr
serum
cytokin
essenti
nk
cell
activ
cytokin
produc
subset
nk
cell
numer
higher
pid
first
compar
second
third
trimest
gilt
figur
unlik
chang
serum
cytokin
concentr
due
cell
frequenc
circul
cell
significantli
differ
treatment
group
data
shown
third
trimest
gilt
numer
higher
mean
concentr
serum
proinflammatori
cytokin
tumor
necrosi
factor
tnf
interferon
ifn
pid
compar
first
second
trimest
gilt
figur
time
point
correspond
gestat
day
gd
third
trimest
gilt
suggest
innat
proinflammatori
cytokin
increas
immedi
prior
parturit
swine
demonstr
human
pregnanc
addit
third
trimest
gilt
numer
higher
mean
serum
concentr
thelper
cell
cytokin
first
trimest
gilt
numer
higher
mean
serum
regulatori
cytokin
respect
compar
second
third
trimest
gilt
pid
figur
higher
circul
pedv
specif
iga
igg
asc
pedv
iga
ab
concentr
serum
cytokin
transform
growth
factor
tgf
matern
bcell
immun
respons
measur
pid
first
second
third
trimest
gilt
second
trimest
gilt
significantli
higher
circul
pedv
iga
igg
asc
pid
compar
first
third
trimest
gilt
figur
b
addit
number
circul
pedv
iga
asc
consist
higher
pedv
igg
asc
first
second
third
trimest
gilt
pid
figur
b
pedv
iga
ab
titer
significantli
higher
second
trimest
gilt
pid
compar
first
trimest
gilt
figur
serum
cytokin
import
iga
classswitch
significantli
higher
pid
remain
numer
higher
pid
second
compar
first
third
trimest
gilt
figur
serum
cytokin
essenti
ab
product
numer
higher
pid
second
trimest
compar
first
third
trimest
gilt
figur
signific
differ
observ
serum
pedv
igg
vn
ab
titer
within
first
week
postpedv
infect
trend
higher
mean
titer
second
trimest
gilt
figur
b
gilt
sampl
pid
asterisk
indic
signific
differ
among
treatment
group
time
point
mean
sem
statist
analysi
perform
use
twoway
anova
repeat
measur
bonferroni
correct
multipl
comparison
p
p
p
standard
asc
ab
respons
among
gilt
treatment
group
uniform
gd
circul
pedv
iga
igg
asc
ab
vn
ab
compar
gd
first
second
third
trimest
pedvinfect
gilt
third
trimest
mock
gilt
second
trimest
gilt
significantli
higher
circul
pedv
iga
igg
asc
gd
compar
first
third
trimest
gilt
figur
b
pedv
iga
asc
consist
higher
pedv
igg
asc
blood
first
second
third
trimest
gilt
gd
figur
b
addit
circul
pedv
iga
igg
asc
first
second
trimest
gilt
continu
decreas
week
prior
parturit
demonstr
parturit
relat
time
postinfect
effect
circul
pedv
iga
igg
asc
observ
third
trimest
gilt
whose
elev
number
pedv
iga
numer
igg
significantli
asc
gd
figur
b
correspond
pedv
rna
shed
fece
pid
figur
second
trimest
gilt
significantli
higher
serum
pedv
iga
ab
titer
compar
first
trimest
gilt
gd
third
trimest
gilt
gd
figur
serum
pedv
igg
ab
titer
significantli
higher
second
compar
first
trimest
gilt
gd
third
trimest
gilt
gd
figur
similarli
pedv
vn
ab
titer
significantli
higher
second
compar
first
trimest
gilt
time
point
significantli
higher
third
trimest
gilt
gd
figur
mean
frequenc
circul
gut
home
phenotyp
b
lymphocyt
second
third
trimest
gilt
significantli
higher
compar
first
trimest
gilt
pid
figur
addit
first
trimest
gilt
delay
increas
b
lymphocyt
frequenc
blood
post
pedv
infect
figur
frequenc
b
lymphocyt
standard
among
gilt
treatment
group
uniform
gd
late
pregnanc
figur
third
trimest
gilt
numer
elev
frequenc
circul
b
lymphocyt
figur
gd
correspond
pedv
rna
shed
fece
pid
figur
mean
frequenc
circul
chemokin
receptor
type
b
lymphocyt
also
measur
post
pedv
infect
figur
standard
among
gilt
treatment
group
uniform
gd
late
pregnanc
figur
statist
differ
among
treatment
group
observ
pid
figur
howev
third
trimest
gilt
significantli
higher
frequenc
circul
b
lymphocyt
gd
pid
compar
second
first
trimest
mock
gilt
figur
increas
circul
b
lymphocyt
gd
correspond
peak
pedv
rna
shed
titer
pid
figur
third
trimest
gilt
addit
significantli
higher
frequenc
activ
b
lymphocyt
observ
blood
second
third
compar
first
trimest
gilt
pid
figur
determin
effect
stage
gestat
time
pedv
infect
lactogen
immun
protect
piglet
challeng
pedv
day
age
number
viabl
piglet
born
statist
signific
treatment
group
figur
second
trimest
pedv
infect
gilt
result
surviv
pedv
challeng
piglet
figur
first
trimest
gilt
provid
intermedi
protect
surviv
third
trimest
gilt
provid
least
amount
protect
surviv
among
pedvinfect
gilt
mock
piglet
surviv
rate
significantli
lower
treatment
group
comparison
piglet
weight
gain
reveal
second
trimest
litter
gain
significantli
weight
treatment
group
start
post
challeng
day
pcd
last
throughout
experi
figur
first
trimest
litter
significantli
higher
normal
weight
third
trimest
litter
pcd
similar
thereaft
mock
litter
stunt
decreas
weight
gain
pcd
lowest
normal
weight
throughout
studi
lactogen
immun
protect
coincid
decreas
pedv
rna
shed
titer
mean
peak
titer
log
copiesml
log
copiesml
log
copiesml
log
copiesml
second
first
third
mock
litter
respect
figur
correspond
increas
weight
gain
decreas
pedv
rna
shed
titer
diarrhea
score
significantli
lower
second
trimest
litter
throughout
studi
figur
first
trimest
litter
diarrhea
delay
significantli
lower
third
trimest
litter
pcd
mock
litter
diarrhea
immedi
pcd
last
pcd
diarrhea
score
significantli
higher
treatment
group
gilt
mean
pedv
rna
shed
titer
fecal
consist
score
measur
post
piglet
challeng
mock
gilt
pedv
rna
shed
titer
significantli
higher
pcd
first
second
third
trimest
pedvinfect
gilt
remain
numer
higher
pcd
figur
addit
first
trimest
gilt
pedv
rna
shed
titer
peak
pcd
earlier
compar
second
third
trimest
gilt
figur
mock
gilt
fecal
consist
score
significantli
higher
pcd
compar
first
second
third
trimest
pedvinfect
gilt
figur
diarrhea
observ
previous
pedvinfect
gilt
post
piglet
challeng
figur
evalu
serum
titer
piglet
pedv
iga
igg
ab
second
trimest
litter
significantli
higher
titer
circul
pedv
iga
ab
figur
compar
first
trimest
litter
pcd
pedv
igg
ab
pcd
figur
addit
compar
third
trimest
litter
second
trimest
litter
higher
titer
pedv
iga
ab
pcd
figur
pedv
igg
ab
pcd
figur
first
trimest
litter
significantli
higher
pedv
iga
igg
ab
titer
pcd
compar
third
trimest
litter
figur
b
lastli
circul
pedv
iga
igg
ab
pcd
posit
correl
surviv
rate
post
piglet
pedv
challeng
figur
colostrum
pedv
iga
igg
asc
significantli
higher
second
compar
first
third
trimest
gilt
figur
b
howev
milk
pedv
iga
asc
significantli
higher
postpartum
day
ppd
second
trimest
gilt
compar
treatment
group
figur
pedv
iga
asc
maintain
high
number
milk
throughout
lactat
milk
pedv
igg
asc
decreas
significantli
throughout
studi
figur
b
similar
asc
pedv
iga
igg
ab
significantli
higher
colostrum
second
compar
first
iga
igg
third
trimest
iga
gilt
figur
addit
pedv
vn
ab
titer
significantli
higher
colostrum
second
compar
third
trimest
gilt
figur
pedv
piglet
challeng
ppd
pedv
iga
ab
titer
milk
significantli
higher
second
compar
third
trimest
gilt
pedv
igg
ab
titer
significantli
higher
second
compar
first
trimest
gilt
figur
lastli
pedv
vn
ab
titer
significantli
higher
milk
ppd
compar
first
third
trimest
gilt
figur
observ
signific
correl
pedv
iga
igg
asc
iga
vn
ab
colostrum
piglet
surviv
tabl
howev
mid
late
lactat
milk
pedv
iga
asc
iga
vn
ab
significantli
correl
piglet
surviv
signific
p
correl
observ
milk
igg
asc
ab
piglet
surviv
tabl
correl
consist
hypothesi
iga
asc
ab
titer
milk
respons
lactogen
immun
protect
neonat
piglet
pedv
challeng
third
trimest
gilt
lower
mean
number
pedv
ab
cell
mg
per
microscop
field
compar
second
first
trimest
gilt
gd
figur
pedv
ab
cell
mg
mock
gilt
prepartum
gd
suggest
significantli
differ
mean
number
pedv
ab
cell
mg
may
reflect
level
pedv
asc
ab
colostrum
exampl
third
trimest
gilt
lowest
mean
number
pedv
ab
cell
per
microscop
field
mg
prepartum
coincid
lowest
mean
number
iga
igg
asc
mean
titer
pedv
iga
vn
ab
colostrum
pedv
ab
cell
also
observ
lactat
mg
pcd
first
second
third
trimest
pedvinfect
gilt
significantli
higher
number
pedv
ab
cell
per
microscop
field
mg
compar
mock
gilt
post
piglet
challeng
figur
differenti
affect
mg
spleen
mesenter
lymph
node
ileum
asc
highest
mean
number
pedv
iga
asc
ileum
highest
mean
number
pedv
igg
asc
spleen
ileum
figur
b
second
trimest
gilt
mean
number
iga
igg
asc
significantli
higher
ileum
third
first
trimest
gilt
respect
howev
mock
gilt
similar
higher
mean
number
iga
igg
asc
spleen
mesenter
lymph
node
mln
ileum
compar
first
second
third
trimest
gilt
figur
b
correspond
higher
pedv
rna
shed
titer
fece
pedvinduc
diarrhea
mock
gilt
figur
b
due
high
mortal
rate
mock
litter
figur
mg
mock
gilt
regress
rapidli
post
piglet
challeng
enough
mg
tissu
left
pcd
collect
mg
mnc
asc
analysi
diarrheal
diseas
repres
major
global
health
burden
lead
caus
morbid
mortal
young
children
anim
specif
emerg
pedv
us
led
million
piglet
death
estim
multimilliondollar
loss
us
swine
industri
matern
vaccin
enhanc
passiv
transfer
protect
ab
milk
induc
via
gutmgsiga
axi
major
strategi
protect
neonat
suckl
piglet
immedi
birth
howev
due
biolog
immunolog
differ
stage
pregnanc
optimum
time
induc
matern
immun
gutmgsiga
axi
previous
undefin
evalu
impact
stage
gestat
pedv
infect
matern
immun
respons
gener
pedvspecif
asc
ab
serum
milk
asterisk
indic
signific
differ
among
treatment
group
time
point
mean
sem
statist
analysi
perform
use
twoway
anova
repeat
measur
bonferroni
correct
multipl
comparison
p
p
p
protect
effect
lactogen
immun
pedvchalleng
piglet
major
find
studi
pedv
infect
second
trimest
optimum
stage
gestat
gener
highest
matern
immun
respons
blood
milk
correl
lactogen
immun
protect
pedv
challeng
suckl
piglet
tabl
exampl
second
trimest
gilt
highest
peak
level
circul
pedv
iga
igg
asc
ab
vn
ab
prior
parturit
interestingli
coincid
higher
serum
cytokin
concentr
significantli
numer
pid
second
trimest
gilt
cytokin
produc
multipl
lineag
leukocyt
stromal
cell
requir
iga
class
switch
recombin
iga
b
cell
surviv
lamina
propria
addit
promot
ab
product
increas
b
cell
helper
capac
cell
data
support
previou
research
demonstr
increas
serum
women
second
trimest
correl
increas
ab
titer
increas
serum
pedv
infect
second
trimest
gilt
like
contribut
enhanc
antipedv
matern
immun
respons
despit
pedvinfect
week
earlier
first
trimest
gilt
gener
lower
matern
immun
respons
gestat
compar
second
trimest
gilt
tabl
suggest
stage
gestat
depend
differ
immun
paramet
may
contribut
differenti
induct
humor
immun
respons
pedv
infect
increas
nk
cell
frequenc
pid
first
compar
second
third
trimest
gilt
first
trimest
second
trimest
gd
third
trimest
gd
agreement
previou
studi
report
increas
number
cytotox
peripher
nk
cell
first
trimest
women
swine
furthermor
significantli
higher
circul
nk
cell
cytotox
pid
coincid
enhanc
mean
concentr
serum
nk
cell
activ
prolifer
cytokin
pid
first
trimest
gilt
increas
peripher
decidu
nk
cell
frequenc
lytic
activ
first
trimest
thought
support
matern
tissu
remodel
embryo
implant
swine
human
addit
nk
cell
known
modul
b
cell
immun
therefor
uniqu
immun
environ
first
trimest
may
impact
b
cell
respons
pedv
infect
pregnant
gilt
futur
studi
investig
effect
nk
cell
matern
immun
respons
enter
viral
infect
gilt
warrant
also
hypothes
stage
gestat
would
impact
b
cell
phenotyp
pre
post
pedv
infect
exampl
lymphocyt
integrin
mucos
adhes
molecul
respons
cellular
migrat
intestin
mucosa
lymphoid
tissu
interact
receptor
mucos
addressin
cellular
adhes
molecul
circul
lymphocyt
reflect
intestin
tissu
prime
may
influenc
gutmgsiga
axi
significantli
higher
frequenc
b
cell
pid
second
third
trimest
compar
first
trimest
gilt
tabl
coincid
increas
concentr
immun
modul
pregnancyassoci
hormon
swine
like
estron
estron
sulfat
sulfat
exampl
traffick
iga
lymphoblast
mg
ovariectom
femal
mice
enhanc
administr
addit
combin
progesteron
administr
ovariectom
femal
mice
result
increas
lselectin
adhes
nk
cell
mucos
tissu
addit
observ
differenti
effect
gestat
stage
prime
andor
activ
b
cell
frequenc
blood
signific
increas
circul
b
cell
frequenc
pid
second
third
trimest
compar
first
trimest
gilt
similar
trend
observ
b
cell
frequenc
later
pregnanc
tabl
increas
concentr
pregnancyassoci
hormon
pregnanc
progress
could
modul
circul
frequenc
b
cell
contribut
differenti
immun
respons
observ
studi
futur
studi
treat
ovariectom
swine
exogen
progesteron
need
deciph
vivo
effect
pregnanc
associ
hormon
mucos
lymphocyt
traffick
b
cell
activ
asc
ab
product
knowledg
first
studi
demonstr
effect
stage
gestat
time
enter
viral
infect
gutmgsiga
axi
immun
protect
suckl
piglet
studi
second
trimest
gilt
provid
greater
passiv
lactogen
immun
protect
compar
first
third
trimest
mock
gilt
increas
level
protect
significantli
correl
pedv
iga
asc
ab
vn
ab
colostrum
milk
tabl
result
agreement
previou
work
done
tgevinfect
pregnant
swine
exampl
high
rate
protect
tgev
piglet
achiev
pregnant
sow
oral
infect
live
virul
viru
increas
rate
protect
associ
high
titer
iga
ab
colostrum
milk
induc
via
gutmgsiga
axi
addit
pedv
iga
igg
ab
titer
piglet
serum
pcd
correl
piglet
protect
pedv
challeng
studi
experiment
infect
gilt
dose
strain
pedv
control
pariti
lack
prior
tgevexposur
therefor
abl
observ
correl
immun
second
trimest
gilt
provid
optim
protect
pedv
challeng
suckl
piglet
correl
level
colostrum
milk
pedv
iga
asc
ab
vn
ab
piglet
serum
iga
igg
ab
tabl
experiment
infect
studi
giltssow
control
pedv
dose
time
piglet
challeng
post
parturit
import
determin
correl
lactogen
immun
protect
pedv
lastli
observ
significantli
higher
pedv
rna
shed
titer
pid
diarrhea
score
pid
third
trimest
gilt
suggest
factor
involv
intestin
homeostasi
impact
hormon
chang
third
trimest
exampl
circul
porcin
growth
hormon
concentr
increas
third
trimest
prior
parturit
grow
evid
hormon
dynam
influenc
gut
microbiom
coincid
gut
microbi
environ
pregnanc
chang
dramat
first
third
trimest
human
swine
result
decreas
bacteri
commun
rich
addit
studi
pedvinfect
pregnant
sow
reveal
signific
decreas
observ
bacteri
speci
compar
healthi
pregnant
sow
although
gut
microbiom
examin
studi
possibl
pregnanc
hormoneinduc
effect
gut
microbiom
late
pregnanc
combin
pedv
infect
result
increas
gut
dysbiosi
third
trimest
pregnant
gilt
futur
studi
investig
impact
microbiom
pregnanc
pedv
pathogenesi
gutmgsiga
axi
warrant
previou
research
investig
stage
gestat
vaccin
immun
respons
pregnant
women
reach
conclus
similar
women
vaccin
tetanusdiphtheriaacellular
pertussi
tdap
vaccin
second
andor
earli
third
trimest
higher
concentr
avid
antitdap
ab
matern
blood
increas
transplacent
antitdap
ab
transfer
compar
women
immun
mid
late
third
trimest
agreement
result
demonstr
second
trimest
pedv
infect
yield
highest
titer
pedv
iga
igg
vn
ab
serum
colostrummilk
research
need
human
livestock
better
understand
matern
immun
design
effect
matern
vaccin
passiv
protect
suckl
neonat
prevent
neonat
morbid
mortal
summari
comparison
pedv
infect
differ
stage
gestat
demonstr
first
second
third
trimest
gilt
immun
respons
vari
greatli
magnitud
immun
respons
associ
lactogen
immun
protect
conclud
second
trimest
gilt
greatest
capac
gener
robust
antipedv
humor
immun
respons
prior
parturit
result
highest
amount
lactogen
immun
protect
pedv
challeng
neonat
suckl
piglet
addit
piglet
protect
pedv
challeng
correl
pedv
iga
asc
iga
ab
vn
ab
milk
pedv
iga
igg
ab
piglet
serum
tabl
result
provid
novel
insight
identifi
possibl
predictor
matern
vaccin
efficaci
passiv
protect
suckl
piglet
final
pregnanc
evalu
singl
event
develop
success
attenu
pedv
vaccin
requir
consider
stage
gestat
time
vaccin
wildtyp
strain
pedv
use
gilt
infect
piglet
challeng
dose
plaqu
form
unit
pfu
dilut
minim
essenti
media
mem
life
technolog
carlsbad
ca
briefli
isol
cultur
vero
cell
describ
previous
cell
grown
growth
medium
contain
dulbecco
modifi
eagl
medium
dmem
life
technolog
carlsbad
ca
supplement
fetal
bovin
serum
life
technolog
carlsbad
ca
antibioticantimycot
life
technolog
carlsbad
ca
viru
grown
vero
cell
mainten
medium
contain
dmem
supplement
trypsin
life
technolog
carlsbad
ca
tryptos
phosphat
broth
sigma
aldrich
st
loui
mo
antibioticantimycot
cell
kept
humidifi
incub
c
co
passag
three
time
vero
cell
passag
gener
inoculum
gnotobiot
pig
virul
pig
passag
confirm
adult
neonat
pig
cellcultur
adapt
use
posit
control
vn
ab
assay
anim
experi
approv
institut
anim
care
use
committe
ohio
state
univers
pig
maintain
sampl
euthan
human
first
pariti
pedv
porcin
deltacoronaviru
pdcov
tgev
seroneg
pregnant
gilt
landrac
yorkshir
duroc
crossbr
acquir
either
wilson
farm
elkhorn
wi
ohio
state
univers
swine
center
facil
randomli
assign
one
four
treatment
group
pedvinfect
first
trimest
gd
n
second
trimest
gd
n
third
trimest
gd
n
meminfect
third
trimest
control
gd
n
figur
second
third
trimest
gilt
arriv
facil
gd
respect
acclim
week
prior
pedv
infect
first
trimest
gilt
hous
pedvinfect
nation
anim
diseas
center
usdaar
ame
iowa
four
gilt
ship
facil
gd
determin
fecal
shed
neg
realtim
quantit
polymeras
chain
reaction
rtqpcr
gilt
fecal
sampl
collect
clinic
sign
observ
pid
fecal
consist
score
follow
solid
pasti
semiliquid
liquid
respect
fecal
consist
score
consid
diarrhea
blood
sampl
collect
postpedv
infect
pid
also
prior
parturit
gd
serum
mononuclear
cell
mnc
isol
gilt
farrow
natur
facil
gd
colostrum
collect
within
h
parturit
piglet
oral
pedvchalleng
day
age
mean
sd
challeng
day
first
trimest
litter
second
trimest
litter
third
trimest
litter
mock
litter
gilt
piglet
serum
collect
pcd
colostrum
milk
sampl
collect
administr
oxytocin
intramuscularli
im
ppd
figur
gilt
mg
biopsi
collect
gd
ppd
piglet
fecal
sampl
collect
clinic
sign
bodi
weight
record
daili
pcd
everi
day
pcd
anim
euthan
pcd
upon
euthanasia
gilt
blood
ileum
mg
mln
spleen
tissu
collect
mnc
isol
piglet
blood
collect
serum
separ
immunolog
assay
determin
pedv
rna
shed
titer
two
rectal
swab
suspend
ml
mem
describ
previous
viral
rna
extract
fecal
supernat
follow
centrifug
g
min
c
use
magmax
viral
rna
isol
kit
appli
biosystem
foster
citi
ca
accord
manufactur
instruct
titer
viral
rna
shed
fece
determin
taqman
rtqpcr
use
onestep
rtpcr
kit
qiagen
valencia
ca
detect
limit
copi
per
reaction
correspond
log
copiesml
origin
fecal
sampl
blood
spleen
mln
ileum
collect
asept
euthanasia
process
mnc
isol
describ
previous
isol
cell
resuspend
enrich
rpmi
erpmi
roswel
park
memori
institut
medium
contain
fetal
bovin
serum
mm
lglutamin
mm
sodium
pyruv
mm
nonessenti
amino
acid
mm
hepe
acid
antibioticantimycot
life
technolog
carlsbad
ca
use
assay
viabil
mnc
determin
trypan
blue
exclus
briefli
mnc
dilut
twofold
trypan
blue
visual
use
autom
cell
counter
cellomet
nexcelom
lawrenc
viabil
calcul
number
blue
cellsnumb
total
cell
mg
collect
asept
euthanasia
place
icecold
wash
medium
rpmi
serum
sampl
process
analyz
proinflammatori
innat
regulatori
cytokin
describ
previous
modif
briefli
nunc
maxisorp
plate
coat
antiporcin
clone
antiporcin
clone
antiporcin
clone
antiporcin
clone
thermo
fisher
scientif
waltham
antiporcin
goat
polyclon
ab
antiporcin
goat
polyclon
ab
antiporcin
porcin
detect
ab
biotinyl
use
commerci
kit
describ
previous
plate
develop
cytokin
concentr
calcul
describ
previous
sensit
cytokin
elisa
assay
pgml
pgml
pgml
pgml
colostrummilk
collect
asept
gilt
given
oxytocin
veton
bois
id
im
facilit
collect
mammari
secret
colostrummilk
place
immedi
ice
sampl
filter
pore
filter
centrifug
g
min
c
separ
fat
skim
milk
cell
pellet
portion
fat
remov
util
steril
plaintip
applic
fisher
scientif
hampton
nh
skim
milk
collect
centrifug
g
h
c
separ
whey
store
c
test
cell
pellet
portion
resuspend
percol
solut
centrifug
g
min
c
cell
pellet
resuspend
percol
underlaid
percol
centrifug
g
min
c
mnc
collect
interfac
wash
wash
medium
cell
filter
pore
filter
resuspend
erpmi
viabil
mnc
prepar
determin
trypan
blue
exclus
blood
mnc
cell
use
effector
target
cell
respect
effector
target
cell
ratio
use
assay
done
describ
previous
determin
frequenc
nk
cell
mnc
identifi
briefli
peripher
blood
mononuclear
cell
pbmc
cellsml
stain
antiporcin
clone
southern
biotech
antiporcin
human
analog
clone
southern
biotech
antiporcin
clone
southern
biotech
monoclon
ab
mab
min
c
subsequ
cell
wash
incub
streptavidin
apc
bd
bioscienc
san
jose
ca
usa
secondari
ab
appropri
isotyp
match
control
ab
includ
acquisit
event
analys
done
use
accuri
flow
cytomet
bd
bioscienc
gate
strategi
depict
figur
plaqu
reduct
vn
assay
perform
describ
previous
modif
serum
whey
inactiv
c
min
prior
test
pedv
neutral
ab
serial
dilut
test
sera
whey
mix
pfu
pfu
pedv
cellcultur
adapt
strain
respect
serumwheyviru
mixtur
incub
h
c
gentl
rock
duplic
sampl
infect
onto
day
confluent
vero
cell
monolay
plate
plate
incub
c
h
lightli
rock
everi
min
subsequ
inoculum
remov
cell
wash
twice
steril
pb
ph
sigma
aldrich
st
loui
mo
overlaid
low
melt
point
agaros
seaplaqu
lonza
riversid
pa
serum
free
media
supplement
tryptos
phosphat
broth
trypsin
describ
pedv
cultiv
plate
incub
c
day
stain
neutral
red
solut
sigma
aldrich
st
loui
mo
plaqu
count
vn
titer
determin
calcul
reciproc
highest
dilut
serumwhey
sampl
show
reduct
number
plaqu
compar
seroneg
control
serumwhey
cell
cultur
adapt
propag
vero
cell
polystyren
roller
bottl
fischer
scientif
hampton
nh
cell
demonstr
cytopath
effect
cpe
roller
bottl
subject
two
freezethaw
cycl
c
collect
supernat
centrifug
g
min
c
remov
vero
cell
debri
supernat
overlay
onto
ml
sucros
tnc
buffer
mm
tri
ph
mm
nacl
mm
cacl
nan
centrifug
g
h
c
viral
pellet
resuspend
tnc
buffer
centrifug
g
h
c
wash
twice
steril
pb
ph
viral
pellet
inactiv
use
binari
ethylenimin
bei
previous
describ
obtain
use
fluoresc
microscop
olympu
mean
number
pedv
ab
cell
evalu
measur
least
differ
microscop
field
magnif
sampl
time
point
gd
pcd
first
second
third
pedvinfect
mock
gilt
procedur
flow
cytometri
stain
includ
buffer
use
perform
describ
previous
minor
modif
briefli
mnc
cellsml
stain
antiporcin
clone
southern
biotech
antiporcin
clone
vmrd
monoclon
ab
mab
determin
b
cell
subset
determin
express
integrin
integrin
cell
stain
porcin
crossreact
antihuman
integrin
clone
abcam
cambridg
antimous
integrin
clone
bd
bioscienc
antimous
clone
r
system
mab
addit
determin
express
iga
cell
stain
antiporcin
iga
clone
biorad
mab
wash
cell
stain
appropri
secondari
antibodi
intracellular
stain
stain
cell
permeabil
cytofixcytoperm
bd
bioscienc
wash
permwash
buffer
bd
bioscienc
stain
porcin
crossreact
antimous
ab
clone
biorad
mab
addit
antiporcin
clone
southern
biotech
antiporcin
clone
southern
biotech
cell
assess
within
antiporcin
clone
southern
biotech
mnc
popul
lymphocyt
appropri
isotyp
match
control
antibodi
includ
acquisit
event
analys
done
use
accuri
flow
cytomet
bd
bioscienc
san
jose
ca
usa
gate
strategi
b
cell
phenotyp
depict
figur
pedv
rna
shed
titer
fecal
consist
score
normal
weight
frequenc
blood
mnc
popul
flow
cytometri
mean
concentr
serum
cytokin
pedv
iga
igg
asc
logtransform
pedv
iga
igg
vn
ab
titer
pedv
ab
cell
mg
analyz
twoway
analysi
varianc
anovagener
linear
model
follow
bonferroni
posttest
nk
cell
activ
blood
pedv
iga
igg
asc
mg
spleen
mln
ileum
tissu
compar
among
group
mannwhitney
nonparametr
test
logrank
mantelcox
test
use
comparison
surviv
curv
amongst
treatment
group
statist
signific
assess
p
comparison
statist
analys
perform
graphpad
prism
graphpad
softwar
inc
ca
studi
approv
institut
anim
care
use
committe
iacuc
perform
gestat
lactat
gilt
piglet
age
week
accord
usda
osu
iacuc
guidelin
ls
kl
sl
contribut
concept
design
studi
sl
conduct
experi
analyz
data
wrote
manuscript
ls
ag
supervis
work
contribut
critic
analysi
result
fp
ab
avg
assist
daili
anim
work
collect
process
sampl
conduct
rtqpcr
experi
analysi
sl
conduct
ihc
experi
analysi
author
contribut
manuscript
revis
read
approv
submit
version
